HuGE Literature Finder
Records
1
-
1
Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Mar . Hill Andrew Graham, Findlay Michael, Burge Matthew, Jackson Christopher, García Alfonso Pilar, Samuel Leslie, Ganju Vinod, Karthaus Meinolf, Amatu Alessio, Jeffery Mark, Di Bartolomeo Maria, Bridgewater John, Coveler Andrew L, Hidalgo Manuel, Kapp Amy V, Sufan Roxana, McCall Bruce, Hanley William, Penuel Elicia, Pirzkall Andrea, Tabernero Jos |
- Page last reviewed:Feb 1, 2023
- Page last updated:Feb 07, 2023
- Content source: